Status:

UNKNOWN

18F-Flutemetamol and Plaque Vulnerability

Lead Sponsor:

Maastricht University Medical Center

Conditions:

Atherosclerosis

Eligibility:

All Genders

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

Rationale: Amyloid beta (Ab) is mainly known for its role in Alzheimer's disease (AD) pathology. However, Ab seems not only to be involved in AD pathology, but also in atherosclerosis, which might exp...

Eligibility Criteria

Inclusion

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • All patients:
  • Age18years and older (no maximum age)
  • Informed consent by signed informed consent form regarding this study
  • Patients, who are scheduled for carotid endarterectomy:
  • o Inclusion criteria for carotid endarterectomy:
  • Symptomatic stenosis (TIA or CVA) within last 14days and high grade stenosis (70-99%)
  • In men, carotid artery stenosis between 50-69% is considered significant when related to clinical symptoms
  • Patients, who are not scheduled for carotid endarterectomy:
  • Patients who have experienced a TIA/CVA/amaurosis fugax (a 'TIA of the eye') within the last 14 days and abnormal findings on imaging of the carotids:
  • Women with an ipsilateral carotid artery stenosis between 30-69% based on duplex ultrasonography, CTA, or MRA
  • Men with an ipsilateral carotid artery stenosis between 30-49% based on duplex ultrasonography, CTA, or MRA
  • Patients meeting inclusion criteria for carotid endarterectomy, but with contra- indications for CEA
  • Exclusion Criteria:
  • All patients:
  • Severe cognitive impairment, neurological deficit or comorbidity causing the study to be too high a burden for the patient or disrupting patient's co- operation with scan procedures
  • Evident other causality for stroke (cardiac embolus, small vessel disease or thrombogenic diathesis)
  • Pregnant women and nursing mothers
  • Contra-indications for MRI (49):
  • Ferromagnetic implants, such as pacemakers and other electronic implants
  • Ferromagnetic (intracerebral) vascular clips
  • Metallic cochlear implants
  • Metallic splinters in eye(s) or other magnetic metallic foreign bodies elsewhere
  • Claustrophobia
  • Relative contra-indications for MRI-contrast agents (50):
  • GFR \<30ml/min/1,73m2
  • Previous allergic reaction to MRI contrast agent
  • Contra-indication 18F-Flutemetamol:
  • Known allergic reaction to flutemetamol or polysorbate 80 or any of the excipients.
  • Severe liver dysfunction.
  • Patients undergoing CEA:
  • Comorbidity associated with high operative risk
  • Occlusion of the internal carotid artery on the symptomatic side
  • Near occlusion on the symptomatic side
  • Complete infarction of the symptomatic anterior circulation/severe neurological deficit

Exclusion

    Key Trial Info

    Start Date :

    February 1 2018

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 31 2019

    Estimated Enrollment :

    25 Patients enrolled

    Trial Details

    Trial ID

    NCT03291093

    Start Date

    February 1 2018

    End Date

    December 31 2019

    Last Update

    July 11 2019

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Maastricht University Medical Centre (MUMC+)

    Maastricht, Limburg, Netherlands, 6229 HX

    18F-Flutemetamol and Plaque Vulnerability | DecenTrialz